We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > IFM Therapeutics

News List

IFM Therapeutics and Novartis Complete Previously Announced Acquisition of IFM Tre firstwordpharma
May 09, 2019
IFM Therapeutics (IFM), a privately-held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system ...
Novartis strengthens anti-inflammatory drugs portfolio with IFM Tre buy pharmatimes
April 02, 2019
In a deal potentially worth $1.6 billion, Novartis is set to acquire IFM Therapeutics' IFM Tre unit.
IFM Therapeutics' inflammation-focused subsidiary debuts with $31M fiercebiotech
July 26, 2018
IFM Therapeutics is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre. The new unit, which starts out with $31 million in series A funding, expects to bring its lead asset into phase 1 in 2019.